Efficacy and cost of etanercept in long-term psoriasis: Rational use in clinical practice

References

• Ferrándiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr. 2014;105:504–9
   PubMedGoogle Scholar
• Ferrándiz C, Bordas X, García-Patos V, et al. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol. 2001;15:20–3
   PubMed Web of Science ®Google Scholar
• Ferrándiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol. 2010;28:81–7
   PubMed Web of Science ®Google Scholar
• Moreno-Ramírez D, Ferrándiz L, Ramírez-Soto G, Muñoyerro MD. Quantitative analysis of drug expenditures variability in dermatology units. Farm Hosp. 2013;37:366–71
   PubMedGoogle Scholar
• Puig L, Carrascosa JM, Carretero G, et al. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Actas Dermosifiliogr. 2013;104:694–709
   PubMedGoogle Scholar
• Dauden E. Introducción. Estructura química de etanercept, farmacocinética y mecanismo de acción. Actas Dermosifiliogr. 2010;101:1–4
   Google Scholar
• Cañete JD, Daudén E, Queiro R, et al. Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study. Actas Dermosifiliogr. 2014;105:216–32
   PubMedGoogle Scholar
• Puig L, Carrascosa JM, Carretero G, et al.; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:694–709
   PubMedGoogle Scholar
• Kastelan M, Puizina-Ivić N, Ceović R, et al. Guidelines for the diagnosis and treatment of psoriasis. Lijec Vjesn. 2013;135:195–200
   PubMedGoogle Scholar
• Marques Pinto G, Filipe P. Guidelines for high-quality use of biologic therapies in adults with plaque psoriasis. Acta Med Port. 2012;25:125–41
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al.; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3 – guidelines on the treatment of psoriasis vulgaris (English version). J Dtsch Dermatol Ges. 2012;10:S1–95
   Web of Science ®Google Scholar
• Hsu S, Papp KA, Lebwohl MG, et al.; National Psoriasis Foundation Medical Board. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95–102
   PubMed Web of Science ®Google Scholar
• Gisondi P, Amerio P, Amoroso GF, et al. Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. G Ital Dermatol Venereol. 2013;148:1–10
   PubMedGoogle Scholar
• Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28:438–53
   PubMed Web of Science ®Google Scholar
• Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24:169–78
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159:1177–85
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol 2012;148:487–94
   PubMedGoogle Scholar
• Enbrel Product Information: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf. Accessed July 15, 2013
   Google Scholar
• Daudén E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23:1374–82
   PubMed Web of Science ®Google Scholar
• Arcese A, Aste N, Bettacchi A, et al. Treating psoriasis with etanercept in Italian clinical practice: prescribing practices and duration of remission following discontinuation. Clin Drug Investig. 2010;30:507–16
   PubMed Web of Science ®Google Scholar
• Ruano J, Isla-Tejera B, Jiménez-Puya R, et al. Long-term cost-effectiveness analysis of etanercept and adalimumab for plaque psoriasis not associated with arthritis. Dermatol Ther (Heidelb). 2013;3:131–42
   PubMedGoogle Scholar
• Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol. 2009;160:670–5
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Puntoni M, Salvini C, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm Venereol. 2011;91:44–9
   PubMed Web of Science ®Google Scholar
• Van Lümig PP, Driessen RJ, Boezeman JB, et al. Long-term efficacy of etanercept for psoriasis in daily practice. Br J Dermatol. 2012;166:445–7
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al.; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–32
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12
   PubMed Web of Science ®Google Scholar